Acurx Pharmaceuticals, Inc.

Acurx ended Q2 2026 with cash of $10.7 million versus $7.6 million at December 31, 2025. Q2 R&D expense was $1.1 million versus $0.5 million a year ago, and Q2 G&A was $1.2 million versus $1.7 million. Net loss was $2.3 million, or $0.53 per diluted share, versus a net loss of $2.2 million, or $1.89 per diluted share, in Q2 2025. For the first six months of 2026, R&D was $1.4 million versus $1.1 million, G&A was $2.6 million versus $3.3 million, and net loss was $3.9 million, or $1.13 per diluted share, versus $4.4 million, or $4.01 per diluted share. The company raised about $2.5 million of gross proceeds through a registered direct offering and $0.8 million under the equity line during the quarter. Management said PATHFINDER is fully funded, enrollment is anticipated to start in the fourth quarter, and the company has cash and remaining equity line access to fund PATHFINDER and operations for at least 1 year. ASPIRE remains contingent on appropriate funding from public or private sources or partnerships.

Dave Luci emphasized regulatory progress, especially the FDA meeting on the development path for ibezapolstat and the agency’s willingness to consider the broader package at a pre-NDA meeting after a single Phase III study and other supporting data. He also highlighted the conditional acceptance and trademark allowance for the brand name Syfbezi, plus new scientific work with Leiden University Medical Center and microbiome-related data that he said strengthen the program. His tone was constructive and confident, but he repeatedly noted that advancing ASPIRE still depends on funding.

Rob Shawah focused on the quarter’s financial mix: cash increased to $10.7 million, R&D rose because of manufacturing and consulting tied to the recurrent CDI program, and G&A declined meaningfully due to lower professional fees, legal costs, and share-based compensation. He also quantified capital raised in the quarter at about $2.5 million gross from the registered direct offering and $0.8 million from the equity line. His comments framed the balance sheet as sufficient for PATHFINDER and near-term operations, while leaving ASPIRE financing unresolved.

Analysts focused on manufacturing readiness, international trial plans, what the FDA would view as sufficiently 'robust' data, and how important PATHFINDER could be for securing a partner to fund ASPIRE. Management said there is plenty of API and formulated product for PATHFINDER and enough API manufacturing with appropriate dating to start ASPIRE. On robustness, they pointed to high-quality trial conduct, consistency across endpoints and geographies, and the new design element of assessing patients 8 weeks after treatment; on funding, they said PATHFINDER is important for partnership discussions and could also support an LPAD pathway for recurrent C. difficile.